ALCJ Fundamental Analysis - CROSSJECT

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ALCJ. ALCJ was compared to 64 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALCJ have multiple concerns. ALCJ has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALCJ had negative earnings in the past year.

ALCJ had a negative operating cash flow in the past year.

In the past 5 years ALCJ always reported negative net income.

In the past 5 years ALCJ always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of ALCJ (-35.89%) is worse than 84.62% of its industry peers.

ALCJ's Return On Equity of -308.38% is on the low side compared to the rest of the industry. ALCJ is outperformed by 90.77% of its industry peers.

		Industry Rank	Sector Rank
ROA	-35.89%
ROE	-308.38%
ROIC	N/A

ROA(3y)-34.88%

ROA(5y)-33.65%

ROE(3y)-354.28%

ROE(5y)-361.76%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALCJ so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALCJ has been increased compared to 1 year ago.

ALCJ has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, ALCJ has a worse debt to assets ratio.

2.2 Solvency

ALCJ has an Altman-Z score of 0.81. This is a bad value and indicates that ALCJ is not financially healthy and even has some risk of bankruptcy.

ALCJ's Altman-Z score of 0.81 is on the low side compared to the rest of the industry. ALCJ is outperformed by 72.31% of its industry peers.

A Debt/Equity ratio of 2.52 is on the high side and indicates that ALCJ has dependencies on debt financing.

ALCJ's Debt to Equity ratio of 2.52 is on the low side compared to the rest of the industry. ALCJ is outperformed by 87.69% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.52
Debt/FCF	N/A
Altman-Z	0.81

ROIC/WACCN/A

WACC7.55%

2.3 Liquidity

ALCJ has a Current Ratio of 0.93. This is a bad value and indicates that ALCJ is not financially healthy enough and could expect problems in meeting its short term obligations.

ALCJ has a worse Current ratio (0.93) than 87.69% of its industry peers.

ALCJ has a Quick Ratio of 0.93. This is a bad value and indicates that ALCJ is not financially healthy enough and could expect problems in meeting its short term obligations.

ALCJ's Quick ratio of 0.59 is on the low side compared to the rest of the industry. ALCJ is outperformed by 87.69% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.93
Quick Ratio	0.59

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALCJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.13%, which is quite good.

Looking at the last year, ALCJ shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)13.13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.07%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 56.77% on average over the next years. This is a very strong growth

ALCJ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 98.55% yearly.

EPS Next Y156.1%

EPS Next 2Y81.69%

EPS Next 3Y56.77%

EPS Next 5YN/A

Revenue Next Year286.35%

Revenue Next 2Y140.35%

Revenue Next 3Y98.55%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCJ. In the last year negative earnings were reported.

With a Price/Forward Earnings ratio of 6.97, the valuation of ALCJ can be described as very cheap.

Compared to the rest of the industry, the Price/Forward Earnings ratio of ALCJ indicates a rather cheap valuation: ALCJ is cheaper than 95.38% of the companies listed in the same industry.

ALCJ is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.59, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.97

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as ALCJ's earnings are expected to grow with 56.77% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y81.69%

EPS Next 3Y56.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALCJ!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CROSSJECT

EPA:ALCJ (11/28/2025, 7:00:00 PM)

2.35

-0.01 (-0.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)09-24 2025-09-24

Earnings (Next)03-25 2026-03-25/amc

Inst Owners0.18%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap122.06M

Revenue(TTM)N/A

Net Income(TTM)-11.26M

Analysts84.44

Price Target3.88 (65.11%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)15.15%

PT rev (3m)15.15%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)123.2%

EPS NY rev (3m)123.2%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)56.94%

Revenue NY rev (3m)-5.53%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.97
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	33.42
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.23

EYN/A

EPS(NY)0.34

Fwd EY14.35%

FCF(TTM)-0.18

FCFYN/A

OCF(TTM)-0.11

OCFYN/A

SpS0

BVpS0.07

TBVpS-0.1

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-35.89%
ROE	-308.38%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-34.88%

ROA(5y)-33.65%

ROE(3y)-354.28%

ROE(5y)-361.76%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	2.52
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	60.88%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.93
Quick Ratio	0.59
Altman-Z	0.81

F-Score3

WACC7.55%

ROIC/WACCN/A

Cap/Depr(3y)131.18%

Cap/Depr(5y)130.12%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)13.13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.07%

EPS Next Y156.1%

EPS Next 2Y81.69%

EPS Next 3Y56.77%

EPS Next 5YN/A

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year286.35%

Revenue Next 2Y140.35%

Revenue Next 3Y98.55%

Revenue Next 5YN/A

EBIT growth 1Y5.02%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year219.31%

EBIT Next 3Y71.59%

EBIT Next 5YN/A

FCF growth 1Y20.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-66.35%

OCF growth 3YN/A

OCF growth 5YN/A

CROSSJECT / ALCJ.PA FAQ

What is the fundamental rating for ALCJ stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA.

What is the valuation status of CROSSJECT (ALCJ.PA) stock?

ChartMill assigns a valuation rating of 4 / 10 to CROSSJECT (ALCJ.PA). This can be considered as Fairly Valued.

What is the profitability of ALCJ stock?

CROSSJECT (ALCJ.PA) has a profitability rating of 0 / 10.

Can you provide the financial health for ALCJ stock?

The financial health rating of CROSSJECT (ALCJ.PA) is 0 / 10.

CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

CROSSJECT / ALCJ.PA FAQ

What is the fundamental rating for ALCJ stock?

What is the valuation status of CROSSJECT (ALCJ.PA) stock?

What is the profitability of ALCJ stock?

Can you provide the financial health for ALCJ stock?